News
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...
Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results